OTLK OUTLOOK THERAPEUTICS INC
Company Analysis
Latest News
🟢 Outlook Therapeutics is trading 10% up today amid biotech-sector strength
Outlook Therapeutics is trading at $0.54, up 10.06%, with biotech-sector strength appearing to be the main context for the October 20 move. - No fresh...
🟢 Outlook Therapeutics is trading 5.5% up today amid biotech sector strength
Outlook Therapeutics is trading at $0.52, up +5.52%, with biotech sector strength potentially contributing; XBI rose 2.10% during the regular session. - No...
🟢 Outlook Therapeutics is trading 5.5% up in pre-market — cause unclear
Outlook Therapeutics is trading at $0.52, up 5.48% in pre-market, with the move’s cause unclear. - No fresh company-specific announcement explaining the...
🟢 Outlook Therapeutics is trading 5.5% up in after-hours trading amid a broad biotech rebound
Outlook Therapeutics is trading 5.48% up at $0.52 in after-hours trading on October 19, 2026, consistent with a broad biotech rebound; no company-specific...
🟢 Outlook Therapeutics is trading 6% up today amid a broad biotech rebound
Outlook Therapeutics is trading at $0.52, up +5.88%, amid a broad biotech rebound; no company-specific catalyst for the gain has been identified. - The XBI...
🟢 Outlook Therapeutics is trading 5% up in after-hours trading
Outlook Therapeutics is trading at $0.51, up 5.31% in after-hours trading, with no confirmed company-specific catalyst identified. - Latest company...
🟢 Outlook Therapeutics is trading 5.8% up today with cause still unclear
Outlook Therapeutics is trading at $0.53, up 5.82% on October 16, 2026, with no confirmed catalyst explaining the gain. - Available reporting does not...
🟢 Outlook Therapeutics is trading 6.1% up today amid a biotech-sector rally
Outlook Therapeutics is trading at $0.50, up 6.13%, amid a biotech-sector rally; available information points to sector sentiment rather than a confirmed...
🟢 Outlook Therapeutics is trading 6.36% up in pre-market; catalyst remains unclear
Outlook Therapeutics is trading 6.36% up in pre-market at $0.50, with no clear catalyst identified. - No clear company-specific announcement dated October 15...
🔴 Outlook Therapeutics is trading 11% down amid broader market and biotech weakness
Outlook Therapeutics is trading at $0.50, down -10.82%, with broader market and biotech weakness a plausible contributor. - No company-specific announcement...
🔴 Outlook Therapeutics is trading 6% down today as biotech weakness may have contributed
Outlook Therapeutics is trading at $0.53, down -5.91%, with biotech-sector weakness a possible contributing factor. - No clear company-specific announcement...
🔴 Outlook Therapeutics is trading 5.4% down with no clear company-specific catalyst identified
Outlook Therapeutics is trading 5.4% lower at $0.55 on October 13, 2026, with no clear company-specific catalyst identified. - Its latest identified release...
🟢 Outlook Therapeutics is trading 5% up today
Outlook Therapeutics is trading 5.48% higher at $0.59 on October 9, 2026; available reporting has not identified a specific reason for the intraday gain. - The...
Outlook Therapeutics' LYTENAVA Enters UnitedHealthcare's Review-at-Launch Process
As of October 1, 2026, UnitedHealthcare has added newly approved LYTENAVA™ (bevacizumab-vikg) to its “Review at Launch” process for provider-administered...
🔴 Outlook Therapeutics is trading 5% down today amid broader biotech and market weakness
Outlook Therapeutics is trading 5.07% lower at $0.56 as biotech and broader markets weaken; no clear company-specific catalyst for the October 8 decline was...
🟢 Outlook Therapeutics is trading 5% up with no clear catalyst identified
Outlook Therapeutics is trading at $0.60, up 5.38%, as of 10:29 a.m. on October 7, 2026; available evidence does not identify a clear catalyst for the gain. -...
🔴 Outlook Therapeutics is trading 5% down
Outlook Therapeutics is trading at $0.54, down 5.37%, with no independently verified fresh catalyst identified. - The supplied alert reports a Nasdaq...
Outlook Therapeutics Receives Nasdaq Non-Compliance Notice for Minimum Bid Price
Outlook Therapeutics, Inc. (OTLK) has received a notice of non-compliance from The Nasdaq Stock Market for failing to maintain a minimum bid price of $1.00 per...
🔴 Outlook Therapeutics is trading 5.4% down with no clear catalyst identified
Outlook Therapeutics is trading at $0.59, with a -5.37% change; no clear company or sector catalyst was identified. - Search results showed no September 30...
🔴 Outlook Therapeutics is trading 5% down amid broad risk-off trading
Outlook Therapeutics is trading 5.19% down at $0.61, with the September 28, 2026 decline coinciding with broad risk-off trading, not a confirmed...